佐力药业(300181) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was CNY 453,488,563.91, representing a 0.90% increase year-over-year, while the year-to-date revenue reached CNY 1,464,947,132.50, up 8.97% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2023 was CNY 89,203,600.05, a 29.14% increase year-over-year, and the year-to-date net profit was CNY 286,865,191.49, reflecting a 40.65% growth[4] - The basic earnings per share for Q3 2023 was CNY 0.1272, up 12.07% year-over-year, with a year-to-date diluted earnings per share of CNY 0.4090, an increase of 22.05%[4] - Total operating revenue for the period reached CNY 1,464,947,132.50, an increase of 8.95% compared to CNY 1,344,402,602.13 in the previous period[18] - Net profit for the period was CNY 292,583,698.54, representing a 36.3% increase from CNY 214,596,952.02 in the previous period[20] - Basic and diluted earnings per share increased to CNY 0.4090 from CNY 0.3351, reflecting a growth of approximately 22%[21] Assets and Liabilities - The company's total assets at the end of Q3 2023 were CNY 3,543,470,789.72, a decrease of 2.63% from the end of the previous year[4] - The company's total assets decreased to CNY 3,543,470,789.72 from CNY 3,639,117,963.07, indicating a reduction in asset base[17] - Total liabilities decreased to CNY 830,182,267.56 from CNY 879,192,754.90, showing a decline in overall liabilities[17] - The total number of common shareholders was 40,247, with the largest shareholder holding 18.52% of the shares[13] - The total equity attributable to shareholders of the parent company was CNY 2,667,380,677.87, slightly down from CNY 2,703,749,664.26, indicating a minor decrease in shareholder equity[17] Cash Flow - Cash flow from operating activities for the year-to-date period was CNY 223,951,981.61, showing a 15.50% increase compared to the previous year[4] - The net cash inflow from operating activities was CNY 223.95 million, an increase of CNY 30.05 million or 15.50% year-on-year, primarily due to the growth in net profit and operating cash inflows[10] - Cash inflow from operating activities reached CNY 1,634,268,265.69, up from CNY 1,358,686,568.10, indicating a growth of about 20%[21] - The net cash flow from operating activities was CNY 223,951,981.61, compared to CNY 193,904,381.17 in the previous period, representing an increase of approximately 15.5%[21] - The net cash outflow from investing activities was CNY 115.15 million, an increase of CNY 52.45 million or 83.66% year-on-year, mainly due to a decrease in net cash inflow from investment products and an increase in long-term asset investments[10] - Cash outflow from investing activities totaled CNY 156,183,883.94, down from CNY 356,584,246.43, showing a reduction of about 56%[22] - The net cash flow from investing activities was -CNY 115,148,365.94, worsening from -CNY 62,695,018.67 in the previous period[22] - The net cash outflow from financing activities was CNY 170.68 million, an increase of CNY 4.61 million or 2.78% year-on-year, primarily due to increased dividend distributions and short-term borrowings[10] - The net cash flow from financing activities was -CNY 170,678,901.88, slightly worsening from -CNY 166,066,812.99 in the previous period[22] Investments and Projects - The company reported a significant increase in construction in progress, which rose to CNY 149,094,700, an increase of 91.01% due to ongoing investments in new projects[7] - The company plans to continue investing in the "Intelligent Traditional Chinese Medicine Production Base Construction and Upgrade Project" and the "Innovative Pharmaceutical Industrialization Project" to enhance its market position[8] - Research and development expenses increased to CNY 58,183,284.31 from CNY 50,502,876.94, highlighting ongoing investment in innovation[18] Other Financial Metrics - The company's cash and cash equivalents were CNY 1,010.08 million, down from CNY 1,082.07 million at the beginning of the year[15] - Accounts receivable increased to CNY 461.29 million from CNY 452.84 million at the beginning of the year[15] - Inventory increased significantly to CNY 400.31 million from CNY 318.83 million at the beginning of the year[15] - The company reported a financial income of CNY 17,342,268.01, significantly higher than CNY 1,791,225.26 in the previous period, indicating improved financial management[18] - Other comprehensive income after tax was reported at CNY -121,960,107.00, compared to CNY -264,556,940.89, reflecting a reduction in losses from other comprehensive income[20] - The report for the third quarter was not audited, indicating that the figures are preliminary and subject to change[23]